JP2005512522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512522A5 JP2005512522A5 JP2003538348A JP2003538348A JP2005512522A5 JP 2005512522 A5 JP2005512522 A5 JP 2005512522A5 JP 2003538348 A JP2003538348 A JP 2003538348A JP 2003538348 A JP2003538348 A JP 2003538348A JP 2005512522 A5 JP2005512522 A5 JP 2005512522A5
- Authority
- JP
- Japan
- Prior art keywords
- mut
- polypeptide
- nucleic acid
- drugs
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 102000039446 nucleic acids Human genes 0.000 claims 20
- 108020004707 nucleic acids Proteins 0.000 claims 20
- 150000007523 nucleic acids Chemical class 0.000 claims 20
- 229940079593 drug Drugs 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 5
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 210000003403 autonomic nervous system Anatomy 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 238000007912 intraperitoneal administration Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims 2
- 238000007914 intraventricular administration Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- 241001260012 Bursa Species 0.000 claims 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 210000003467 cheek Anatomy 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000000409 cytokine receptor agonist Substances 0.000 claims 1
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 238000007919 intrasynovial administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34371701P | 2001-10-26 | 2001-10-26 | |
| PCT/US2002/034381 WO2003035847A2 (en) | 2001-10-26 | 2002-10-25 | Il-13 mutein proteins, antibodies, compositions, methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512522A JP2005512522A (ja) | 2005-05-12 |
| JP2005512522A5 true JP2005512522A5 (enExample) | 2006-01-05 |
Family
ID=23347323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003538348A Pending JP2005512522A (ja) | 2001-10-26 | 2002-10-25 | Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040023337A1 (enExample) |
| EP (1) | EP1578912A4 (enExample) |
| JP (1) | JP2005512522A (enExample) |
| CA (1) | CA2464695A1 (enExample) |
| WO (1) | WO2003035847A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040234499A1 (en) * | 2001-10-26 | 2004-11-25 | David Shealy | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| ATE549064T1 (de) | 2002-06-14 | 2012-03-15 | Us Gov Health & Human Serv | Verfahren zur behandlung und prävention von kolitis, die il-13 und nk-t zellen betrifft |
| US20070104710A1 (en) * | 2002-06-28 | 2007-05-10 | Domants Limited | Ligand that has binding specificity for IL-4 and/or IL-13 |
| US20110223168A1 (en) * | 2002-12-27 | 2011-09-15 | Greg Winter | Ligand that has binding specificity for il-4 and/or il-13 |
| EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| KR101073590B1 (ko) * | 2003-07-15 | 2011-10-14 | 메디뮨 리미티드 | Ｉｌ-13에 대한 인간 항체 분자 |
| SG10201404273QA (en) | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
| EP1720573A4 (en) * | 2004-02-27 | 2008-04-02 | Centocor Inc | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH IL-13 |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| JP2008520684A (ja) * | 2004-11-17 | 2008-06-19 | アブジェニックス・インコーポレーテッド | Ｉｌ−１３に対する完全ヒトモノクローナル抗体 |
| BRPI0616359B8 (pt) | 2005-09-30 | 2022-08-30 | Medimmune Ltd | Composição farmacêutica, processo para purificação de um anticorpo de il-13 e uso de uma composição farmacêutica contendo um anticorpo |
| NZ567124A (en) | 2005-10-21 | 2011-08-26 | Novartis Ag | Human antibodies against Interleukin-13 and therapeutic uses to treat asthma |
| ES2371287T3 (es) * | 2006-06-21 | 2011-12-29 | Apogenix Gmbh | Expresión diferencial de la citocina en cáncer humano. |
| WO2008003514A2 (en) * | 2006-07-06 | 2008-01-10 | Apogenix Gmbh | Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| MX2011001909A (es) * | 2008-08-20 | 2011-03-21 | Centocor Ortho Biotech Inc | Anticuerpos anti-interleucina-13 modificados, composiciones, metodos y usos. |
| WO2010121125A1 (en) | 2009-04-17 | 2010-10-21 | Wake Forest University Health Sciences | Il-13 receptor binding peptides |
| SG176000A1 (en) * | 2009-05-13 | 2011-12-29 | Protein Delivery Solutions Llc | Pharmaceutical system for trans-membrane delivery |
| EP3447491A3 (en) | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
| TWI700093B (zh) | 2011-03-16 | 2020-08-01 | 法商賽諾菲公司 | 雙重ｖ區類抗體蛋白質之用途 |
| TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| BR112016004437A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit |
| SG11201601823TA (en) | 2013-09-13 | 2016-04-28 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| RU2694980C2 (ru) | 2014-04-11 | 2019-07-18 | Новартис Аг | Способы избирательного лечения астмы с использованием антагонистов il-13 |
| TW201628647A (zh) | 2014-06-27 | 2016-08-16 | 賽諾菲公司 | 抗－ｉｌ４－ｉｌ１３雙特異性抗體 |
| CN113101364B (zh) | 2018-05-29 | 2023-12-01 | 康诺亚生物医药科技（成都）有限公司 | 一种自免疫抑制剂的开发和应用 |
| EP3976181A1 (en) | 2019-05-24 | 2022-04-06 | Sanofi | Methods for treating systemic sclerosis |
| US20220378877A1 (en) * | 2019-11-13 | 2022-12-01 | University Of Virginia Patent Foundation | Treatment of clostridium difficile infections |
| AU2021395729A1 (en) | 2020-12-07 | 2023-07-13 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60032908T2 (de) * | 1999-08-02 | 2007-06-28 | The Regents Of The University Of Michigan, Ann Arbor | Zielgerichtete fiberlose radiative effektoren |
| ATE540695T1 (de) * | 2001-06-08 | 2012-01-15 | Genaera Corp | Verfahren zur modulation von il-13 |
-
2002
- 2002-10-25 EP EP02793830A patent/EP1578912A4/en not_active Withdrawn
- 2002-10-25 JP JP2003538348A patent/JP2005512522A/ja active Pending
- 2002-10-25 WO PCT/US2002/034381 patent/WO2003035847A2/en not_active Ceased
- 2002-10-25 US US10/280,645 patent/US20040023337A1/en not_active Abandoned
- 2002-10-25 CA CA002464695A patent/CA2464695A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512522A5 (enExample) | ||
| JP2007508011A5 (enExample) | ||
| JP5918909B2 (ja) | 標的化治療薬 | |
| AU2002324625B2 (en) | Interleukin-1 receptors in the treatment of diseases | |
| JP2019059730A (ja) | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン | |
| ES2680222T3 (es) | Modulación de los receptores con dominio Vps10p para el tratamiento de la enfermedad cardiovascular | |
| JP2012506695A5 (enExample) | ||
| KR20190094222A (ko) | 다가 조절성 t 세포 조절제 | |
| JP6921755B2 (ja) | 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物 | |
| HRP20140982T1 (hr) | Ljudska anti-il-23 antitijela, pripravci, postupci i upotrebe | |
| CN103459595B (zh) | 针对人前列腺素e2受体ep4的抗体 | |
| KR20210132749A (ko) | 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) | |
| TW200529853A (en) | Method of treatment of transplant rejection | |
| EP1575511A2 (en) | A new target for angiogenesis and anti-angiogenesis therapy | |
| JP2010534664A5 (enExample) | ||
| CA2609349A1 (en) | Anti-mcp-1 antibodies, compositions, methods and uses | |
| JP2011517548A5 (enExample) | ||
| CN111417647A (zh) | 新型senolytic肽 | |
| ES2713068T3 (es) | Derivados de IGFBP-3 y usos de los mismos | |
| JP2022536289A (ja) | 抗炎症剤 | |
| TW202237634A (zh) | 用於治療ｃｏｖｉｄ－１９之ｄｓｇ２組成物和方法 | |
| US8101580B2 (en) | Therapeutic agent for irritable bowel syndrome | |
| US20230190891A1 (en) | Method and drug for treating spinal muscular atrophy | |
| KR20150070180A (ko) | 근위축성 측삭 경화증 치료제 | |
| JP2023523568A (ja) | ＡｃｔＲＩＩＢリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法 |